Phio Pharmaceuticals (PHIO) Cash & Equivalents (2011 - 2026)

Phio Pharmaceuticals (PHIO) has 16 years of Cash & Equivalents data on file, last reported at $17.0 million in Q1 2026.

• Quarterly Cash & Equivalents rose 28.26% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.0 million (up 28.26% YoY) and the FY2025 annual result came in at $21.0 million, up 290.77% from the prior year.
• Cash & Equivalents slipped to $17.0 million in Q1 2026, from $21.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $21.0 million in Q4 2025 to a low of $4.7 million in Q2 2024.
• A 5-year average of $11.6 million and a median of $10.8 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents plunged 58.45% — and 2025, when it jumped 290.77%.
• Tracing PHIO's Cash & Equivalents over 5 years: stood at $11.8 million in 2022, then retreated by 27.93% to $8.5 million in 2023, then plunged by 36.61% to $5.4 million in 2024, then jumped by 290.77% to $21.0 million in 2025, then declined by 19.02% to $17.0 million in 2026.
• The last three Cash & Equivalents figures came in at $17.0 million (Q1 2026), $21.0 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.